Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: A phase II trial

European Journal of Cancer

Volumn 38, Issue 5, 2002, Pages 654-660

  Laack, E ^a   Mende, T ^a   Durk H ^b   Kneba, M ^c   Dickgreber, N ^d   Welte, T ^d   Muller T ^e   Scholtze, J ^f   Graeven, U ^g   Jasiewicz, Y ^h   Edler, L ^h   Hossfeld, D K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b St Marien Hospital Hamm   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Knappschaftskrankenhaus   (Germany)

^e Hospital Hofheim   (Germany)

^f St Hedwig Klinik GmbH   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chemotherapy; Cisplatin; Gemcitabine; Non small cell lung cancer; Phase II trial; Vinorelbine

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; THROMBOCYTOPENIA; TOXICITY; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036210147     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00346-X     Document Type: Article

References (45)

1. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
2. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
3. Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough?
4. Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients
5. Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer
6. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study
7. Gemcitabine - A safety overview
8. Vinorelbine: An overview
9. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study
10. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study
11. A phase II study of navelbine in the treatment of non-small cell lung cancer
12. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated non-small cell lung cancer
13. Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended phase II study
14. Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer
15. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
16. Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non-small cell lung carcinoma
17. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer
18. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest oncology group study
19. Design, analysis, and reporting of cancer clinical trials
20. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer
21. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small cell lung cancer
22. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer
23. Vinorelbine-gemcitabine in advanced non-small cell lung cancer (NSCLC): An AASLC phase II trial
24. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: A phase II trial
25. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses
26. Chemotherapy of stage IIIb and IV non-small cell lung cancer. Symposium article
27. Chemotherapy of non-small cell lung cancer according to disease extent: A meta-analysis of the literature
28. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small cell lung cancer: A phase II randomized study of the Southern Italy Cooperative Oncology Group
29. A phase I/II study of gemcitabine, cisplatin and vinorelbine in patients with advanced non-small cell lung cancer (NSCLC)
30. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small cell lung cancer: A phase I study
31. A phase II study of gemcitabine, cisplatin and vinorelbine in patients with advanced non-small cell lung cancer (NSCLC)
32. A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC)
33. Gemcitabine, paclitaxel, and carboplatin for advanced non-small cell lung cancer
34. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer (NSCLC)
35. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small cell lung cancer: A phase I-II study
36. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small cell lung cancer (NSCLC)
37. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian Oncology Group for clinical research
38. Non-cisplatin based chemotherapy for advanced non-small cell lung cancer (NSCLC): A phase II study with gemcitabine (G), ifosfamide (I) and vinorelbine (V)
39. Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study
40. Carboplatin, ifosfamide and vinorelbine in the treatment of advanced non-small cell lung cancer: A phase II study
41. Paclitaxel-carboplatin alone or with gemcitabine or vinorelbine for stage IV and IIIB non-small cell lung cancer: Long term follow up
42. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: A randomized phase III study of the Italian lung cancer project
43. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group
44. Interim analysis of a phase III trial. Triple- vs double agent chemotherapy for advanced non-small cell lung cancer
45. Preliminary results of a randomized study comparing paclitaxel and carboplatin (PC) with or without gemcitabine (G) in newly diagnosed non-small cell lung cancer (NSCLC)